With only $1.5M cash and no financing lined up, INDP faces imminent going-concern risk. The strategic review likely targets a reverse merger or asset sale. Traders should watch for a dilutive offering, reverse split, or bankruptcy filing within weeks. The 51x share dilution from preferred conversion makes any recovery extremely challenging for common holders.
Price Chart
Executive Summary
Indaptus Therapeutics reported Q1 2026 results with a net loss of $2.5M ($0.23/share), improved from $4.5M ($9.11/share) a year ago, driven by a 78% reduction in R&D spend as the company paused its Phase 1 study. Cash burn accelerated to $7.0M in operating cash flow, leaving only $1.5M in cash — roughly 2 months of runway — forcing a strategic review and potential sale or reverse merger. The preferred stock conversion eliminated overhang but diluted common shares massively (from 2.2M to 113.2M shares outstanding).
Key Financial Metrics
Key Facts
- Net loss improved to $2.5M from $4.5M YoY, but solely due to R&D cuts from $2.8M to $0.5M after halting the Phase 1 study
- Cash and equivalents fell 82% to $1.5M from $8.5M at year-end 2025, with operating cash burn of $7.0M in the quarter
- All Series AA and AAA preferred stock converted to common, increasing shares outstanding from 2.2M to 113.2M (51x dilution)
- Company explicitly states it needs additional capital and there is no assurance financing will be available
- Management is conducting a strategic review of development priorities and resource allocation, signaling potential pivot or sale
Financial Impact
Cash runway of ~2 months at current burn rate; $1.5M cash vs $7.0M quarterly operating cash use
Risk Factors
- Imminent going-concern risk — cash likely exhausted by mid-2026 without financing
- Massive dilution from preferred conversion (113M shares vs 2.2M) crushes per-share value
- No revenue, no pipeline advancement, and a strategic review that may result in a dilutive reverse merger or liquidation
- Nasdaq listing at risk if stock price remains below $1.00 (current market cap $4M)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295732 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $2.56 $3.93 | ▼ −53.52% | ▼ −52.89% | $2.38 (+7.03%) |
Sep 4, 2026 28d ago | 424B5 | $1.85 $3.64 | ▼ −96.76% | ▼ −97.88% | $2.38 (−28.65%) |
Sep 1, 2026 4w ago | 8-K | $1.13 $2.08 | ▼ −84.07% | ▼ −83.99% | $2.38 (−110.62%) |
Aug 26, 2026 5w ago | EFFECT | $1.14 $1.17 | ▼ −2.63% | ▼ −2.75% | $2.38 (−108.77%) |
Aug 17, 2026 6w ago | S-3 | $0.9361 $1.10 | ▼ −16.97% | ▼ −17.18% | $2.38 (−154.25%) |
Aug 13, 2026 7w ago | 8-K | $1.06 $1.38 | ▲ +30.19% | ▲ +32.15% | $2.38 (+124.53%) |
Jul 20, 2026 10w ago | EFFECT | $2.46 $2.61 | ▼ −6.10% | ▼ −6.52% | $2.38 (+3.25%) |
Jun 26, 2026 13w ago | S-3 | $3.06 $2.85 | ▲ +6.86% | ▲ +8.25% | $2.38 (+22.22%) |
Jun 24, 2026 14w ago | 8-K | $3.26 $2.94 | ▲ +9.82% | ▲ +11.38% | $2.38 (+26.99%) |
May 15, 2026 20w ago | 8-K | $1.59 $1.22 | ▲ +23.27% | ▲ +24.23% | $2.38 (−49.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access